Over 30 million people are at risk of invasive aspergillosis each year due to use of corticosteroids, chemotherapy or other immunosuppressive agents, and over 300,000 patients develop it annually. 1
Timely diagnosis and initiation of therapy strongly influence outcome. IMMY’s lateral flow assay can detect Aspergillus biomarkers in under an hour.
1) Invasive Aspergillosis. Leading International Fungal Education. https://www.life-worldwide.org/fungal-diseases/invasive-aspergillosis
The clinical performance of the IMMY sona Aspergillus Lateral Flow Assay in serum samples from cases classified as proven/probable/chronic IA/IFD (n=32) using EORTC/MSG criteria and control patients with no evidence of IFD (n=100).
Sensitivity | Specificity | PPV | NPV |
---|---|---|---|
97% | 98% | 94% | 99% |
In serum samples, the AGM LFA will correctly generate a positive result for 97% of patients with IA, and a negative result for 98% of patients without IA. The PPV shows that among patients with a positive AGM LFA result, the probability that they truly have IA is 94%. NPV shows that among patients with a negative AGM LFA result, the probability that they do not have IA is 99%. 2
The diagnostic performance of the IMMY sona Aspergillus Lateral Flow Assay in BAL samples from hematology patients classified as proven IPA (n=11) using EORTC/MSG criteria and control patients with no evidence of IPA (n=117).
Sensitivity | Specificity | NPV |
---|---|---|
91% | 92% | 99% |
In BAL samples, the AGM LFA will correctly generate a positive result for 91% of patients with IA, and a negative result for 92% of patients without IA. The NPV shows that among patients with a negative AGM LFA result, the probability that they do not have IA is 99%. 3
Aspergillus Galactomannan LFA | 50 tests | AF2003 |
---|